Non-transmissible MV Vector with Segmented RNA Genome Establishes Different Types of iPSCs from Hematopoietic Cells

Takafumi Hiramoto, Maino Tahara, Jiyuan Liao, Yasushi Soda, Yoshie Miura, Ryo Kurita, Hiroshi Hamana, Kota Inoue, Hiroshi Kohara, Shohei Miyamoto, Yasuki Hijikata, Shinji Okano, Yoshiyuki Yamaguchi, Yoshinao Oda, Kenji Ichiyanagi, Hidehiro Toh, Hiroyuki Sasaki, Hiroyuki Kishi, Akihide Ryo, Atsushi MuraguchiMakoto Takeda, Kenzaburo Tani

研究成果: ジャーナルへの寄稿記事

抄録

Recent advances in gene therapy technologies have enabled the treatment of congenital disorders and cancers and facilitated the development of innovative methods, including induced pluripotent stem cell (iPSC) production and genome editing. We recently developed a novel non-transmissible and non-integrating measles virus (MV) vector capable of transferring multiple genes simultaneously into a wide range of cells through the CD46 and CD150 receptors. The MV vector expresses four genes for iPSC generation and the GFP gene for a period of time sufficient to establish iPSCs from human fibroblasts as well as peripheral blood T cells. The transgenes were expressed differentially depending on their gene order in the vector. Human hematopoietic stem/progenitor cells were directly and efficiently reprogrammed to naive-like cells that could proliferate and differentiate into primed iPSCs by the same method used to establish primed iPSCs from other cell types. The novel MV vector has several advantages for establishing iPSCs and potential future applications in gene therapy. This new non-transmissible and non-integrating measles virus vector, which can transfer multiple genes simultaneously into a wide range of cells through the CD46 and CD150 receptors and induce primed or naive-like pluripotent stem cells from hematopoietic cells in the same condition, will definitely contribute to the gene and cell therapy.

元の言語英語
ジャーナルMolecular Therapy
DOI
出版物ステータス受理済み/印刷中 - 1 1 2019

Fingerprint

Measles virus
Genome
RNA
Genetic Therapy
Induced Pluripotent Stem Cells
Hematopoietic Stem Cells
Genes
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Pluripotent Stem Cells
Gene Order
Cell- and Tissue-Based Therapy
Transgenes
Blood Cells
Fibroblasts
Technology
T-Lymphocytes
Neoplasms

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

これを引用

Non-transmissible MV Vector with Segmented RNA Genome Establishes Different Types of iPSCs from Hematopoietic Cells. / Hiramoto, Takafumi; Tahara, Maino; Liao, Jiyuan; Soda, Yasushi; Miura, Yoshie; Kurita, Ryo; Hamana, Hiroshi; Inoue, Kota; Kohara, Hiroshi; Miyamoto, Shohei; Hijikata, Yasuki; Okano, Shinji; Yamaguchi, Yoshiyuki; Oda, Yoshinao; Ichiyanagi, Kenji; Toh, Hidehiro; Sasaki, Hiroyuki; Kishi, Hiroyuki; Ryo, Akihide; Muraguchi, Atsushi; Takeda, Makoto; Tani, Kenzaburo.

:: Molecular Therapy, 01.01.2019.

研究成果: ジャーナルへの寄稿記事

Hiramoto, T, Tahara, M, Liao, J, Soda, Y, Miura, Y, Kurita, R, Hamana, H, Inoue, K, Kohara, H, Miyamoto, S, Hijikata, Y, Okano, S, Yamaguchi, Y, Oda, Y, Ichiyanagi, K, Toh, H, Sasaki, H, Kishi, H, Ryo, A, Muraguchi, A, Takeda, M & Tani, K 2019, 'Non-transmissible MV Vector with Segmented RNA Genome Establishes Different Types of iPSCs from Hematopoietic Cells', Molecular Therapy. https://doi.org/10.1016/j.ymthe.2019.09.007
Hiramoto, Takafumi ; Tahara, Maino ; Liao, Jiyuan ; Soda, Yasushi ; Miura, Yoshie ; Kurita, Ryo ; Hamana, Hiroshi ; Inoue, Kota ; Kohara, Hiroshi ; Miyamoto, Shohei ; Hijikata, Yasuki ; Okano, Shinji ; Yamaguchi, Yoshiyuki ; Oda, Yoshinao ; Ichiyanagi, Kenji ; Toh, Hidehiro ; Sasaki, Hiroyuki ; Kishi, Hiroyuki ; Ryo, Akihide ; Muraguchi, Atsushi ; Takeda, Makoto ; Tani, Kenzaburo. / Non-transmissible MV Vector with Segmented RNA Genome Establishes Different Types of iPSCs from Hematopoietic Cells. :: Molecular Therapy. 2019.
@article{4c00673faddd4f5d9e9ed630f62e6013,
title = "Non-transmissible MV Vector with Segmented RNA Genome Establishes Different Types of iPSCs from Hematopoietic Cells",
abstract = "Recent advances in gene therapy technologies have enabled the treatment of congenital disorders and cancers and facilitated the development of innovative methods, including induced pluripotent stem cell (iPSC) production and genome editing. We recently developed a novel non-transmissible and non-integrating measles virus (MV) vector capable of transferring multiple genes simultaneously into a wide range of cells through the CD46 and CD150 receptors. The MV vector expresses four genes for iPSC generation and the GFP gene for a period of time sufficient to establish iPSCs from human fibroblasts as well as peripheral blood T cells. The transgenes were expressed differentially depending on their gene order in the vector. Human hematopoietic stem/progenitor cells were directly and efficiently reprogrammed to naive-like cells that could proliferate and differentiate into primed iPSCs by the same method used to establish primed iPSCs from other cell types. The novel MV vector has several advantages for establishing iPSCs and potential future applications in gene therapy. This new non-transmissible and non-integrating measles virus vector, which can transfer multiple genes simultaneously into a wide range of cells through the CD46 and CD150 receptors and induce primed or naive-like pluripotent stem cells from hematopoietic cells in the same condition, will definitely contribute to the gene and cell therapy.",
author = "Takafumi Hiramoto and Maino Tahara and Jiyuan Liao and Yasushi Soda and Yoshie Miura and Ryo Kurita and Hiroshi Hamana and Kota Inoue and Hiroshi Kohara and Shohei Miyamoto and Yasuki Hijikata and Shinji Okano and Yoshiyuki Yamaguchi and Yoshinao Oda and Kenji Ichiyanagi and Hidehiro Toh and Hiroyuki Sasaki and Hiroyuki Kishi and Akihide Ryo and Atsushi Muraguchi and Makoto Takeda and Kenzaburo Tani",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ymthe.2019.09.007",
language = "English",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Non-transmissible MV Vector with Segmented RNA Genome Establishes Different Types of iPSCs from Hematopoietic Cells

AU - Hiramoto, Takafumi

AU - Tahara, Maino

AU - Liao, Jiyuan

AU - Soda, Yasushi

AU - Miura, Yoshie

AU - Kurita, Ryo

AU - Hamana, Hiroshi

AU - Inoue, Kota

AU - Kohara, Hiroshi

AU - Miyamoto, Shohei

AU - Hijikata, Yasuki

AU - Okano, Shinji

AU - Yamaguchi, Yoshiyuki

AU - Oda, Yoshinao

AU - Ichiyanagi, Kenji

AU - Toh, Hidehiro

AU - Sasaki, Hiroyuki

AU - Kishi, Hiroyuki

AU - Ryo, Akihide

AU - Muraguchi, Atsushi

AU - Takeda, Makoto

AU - Tani, Kenzaburo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Recent advances in gene therapy technologies have enabled the treatment of congenital disorders and cancers and facilitated the development of innovative methods, including induced pluripotent stem cell (iPSC) production and genome editing. We recently developed a novel non-transmissible and non-integrating measles virus (MV) vector capable of transferring multiple genes simultaneously into a wide range of cells through the CD46 and CD150 receptors. The MV vector expresses four genes for iPSC generation and the GFP gene for a period of time sufficient to establish iPSCs from human fibroblasts as well as peripheral blood T cells. The transgenes were expressed differentially depending on their gene order in the vector. Human hematopoietic stem/progenitor cells were directly and efficiently reprogrammed to naive-like cells that could proliferate and differentiate into primed iPSCs by the same method used to establish primed iPSCs from other cell types. The novel MV vector has several advantages for establishing iPSCs and potential future applications in gene therapy. This new non-transmissible and non-integrating measles virus vector, which can transfer multiple genes simultaneously into a wide range of cells through the CD46 and CD150 receptors and induce primed or naive-like pluripotent stem cells from hematopoietic cells in the same condition, will definitely contribute to the gene and cell therapy.

AB - Recent advances in gene therapy technologies have enabled the treatment of congenital disorders and cancers and facilitated the development of innovative methods, including induced pluripotent stem cell (iPSC) production and genome editing. We recently developed a novel non-transmissible and non-integrating measles virus (MV) vector capable of transferring multiple genes simultaneously into a wide range of cells through the CD46 and CD150 receptors. The MV vector expresses four genes for iPSC generation and the GFP gene for a period of time sufficient to establish iPSCs from human fibroblasts as well as peripheral blood T cells. The transgenes were expressed differentially depending on their gene order in the vector. Human hematopoietic stem/progenitor cells were directly and efficiently reprogrammed to naive-like cells that could proliferate and differentiate into primed iPSCs by the same method used to establish primed iPSCs from other cell types. The novel MV vector has several advantages for establishing iPSCs and potential future applications in gene therapy. This new non-transmissible and non-integrating measles virus vector, which can transfer multiple genes simultaneously into a wide range of cells through the CD46 and CD150 receptors and induce primed or naive-like pluripotent stem cells from hematopoietic cells in the same condition, will definitely contribute to the gene and cell therapy.

UR - http://www.scopus.com/inward/record.url?scp=85074402497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074402497&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2019.09.007

DO - 10.1016/j.ymthe.2019.09.007

M3 - Article

C2 - 31677955

AN - SCOPUS:85074402497

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

ER -